NEW YORK (360Dx) – Quest Diagnostics announced today it has acquired specialized anatomic pathology service firm PhenoPath.
The deal, whose terms were not disclosed, continued a buying spree for Quest this week, which included the acquisitions of Oxford Immunotec's US lab business and fertility and fertility diagnostics services firm ReproSource.
PhenoPath is based in Seattle and provides anatomic pathology, molecular oncology, and other services such as genetic sequencing and genomic tumor analysis. It will operate as part of AmeriPath, a wholly owned subsidiary of Quest.
"Our acquisition of PhenoPath delivers on our accelerate growth strategy for advanced diagnostics," Quest Chairman, President, and CEO Steve Rusckowski said in a statement. "PhenoPath has a strong record of innovation and provides several capabilities that complement and extend our own, particularly in pathology and molecular oncology. It also deepens our presence in the Pacific Northwest."
Separately, Quest said on Wednesday that is partnering with Regional Medical Center Health System to  provide it supply chain expertise and run laboratory reference testing. RMC provides healthcare services in northeast Alabama.
Quest, headquartered in Secaucus, New Jersey, will manage lab equipment, supplies, and procurement processes for RMC and Stringfellow Memorial Hospital in Anniston, Alabama, as well as provide reference testing for both systems. Financial and other terms of the deal were not disclosed.